Citations

Clear

8 citation(s) found for "Su, Yajuan".

Improved overall survival in classical Hodgkin lymphoma across therapeutic eras: A National Cancer Database study
Gao, Yajuan , Grant, Spears M., Hwang, Steven R. , Thanarajasingam, Gita , Khurana, Arushi , Wang, Yucai , Nowakowski, Grzegorz S., Ansell, Stephen M. , Abeykoon, Jithma P. , Wang, Julia, Gao, Yajuan , Hwang, Steven R , Durani, Urshila , Paludo, Jonas , Wang, Yucai , Habermann, Thomas , Witzig, T.E. , Ansell, Stephen M , Abeykoon, Jithma P , Wang, Julia , Durani, Urshila , Paludo, Jonas , Nowakowski, Grzegorz S. , Habermann, Thomas M. , Witzig, Thomas E.

Mayo Clinic

British Journal of Haematology | September 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/bjh.70776 | PMID 42676284 Get It

Cell-type specific allelic dampening of sex-linked genes in sex chromosome aneuploidy
Filippova, G. N. , Sanger, Elliott M., MacDonald, James, Fang, He, Groneck, Camille, Takasaki, Masaya, Meleshko, A. N., Liu, Yajuan , Li, Gang , Dyke, Daniel Van, Gravholt, Claus H., Bammler, Theo K. , Young, Jessica E., Berletch, Joel B. , Van Dyke, Daniel, Gravholt, Claus H , Noble, William S , Deng, Xinxian , Berletch, Joel B , Sanger, Elliott, Fang, He, Ma, Wenxiu , ZHANG, RAN, Murry, Charles E. , Dyke, Daniel L. Van , Skakkebæk, Anne , Gravholt, Claus Højbjerg , Distèche, Christine M.

Mayo Clinic

No container title available | April 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.16.719032 | PMID 42079153 Get It

Common sex chromosome aneuploidies (SCAs) often present with cognitive and cardiovascular dysfunction in humans. To address SCA effects on gene expression and DNA methylation in relevant cell types, we differentiated neural precursor cells (NPCs) and cardiomyocytes (CMs) from human induced pluripotent stem cells (hiPSCs) with different numbers of sex chromosomes, including isogenic and independent lines. As expected, the expression of genes that escape X inactivation (escapees) mostly increases with the number of inactive X chromosomes (Xi). However, allelic analysis shows dampening of escapees specifically on the Xi in XXY compared to XX in both NPCs and CMs, revealing a novel type of dosage compensation in SCA. In contrast, Y-linked gene expression is higher in XXY versus XY NPCs, but the opposite is observed in CMs. This may explain the greater number of differentially expressed autosomal genes in NPCs versus CMs with an added Y chromosome, while effects of added X chromosomes are similar between cell types. Concordantly, changes in autosomal DNA methylation are mainly driven by the presence of a Y chromosome. These findings highlight the cell-type specificity of sex-linked and autosomal gene regulation in SCA conditions.
Microparticle Mediated Delivery of Apelin Improves Heart Function in Post Myocardial Infarction Mice
Tang, Ling , Qiu, Huiliang , Xu, Bing , Su, Yajuan , Nyarige, Verah , Li, Pengsheng , Chen, Houjia, Killham, Brady , Adám, H , Yang, Aaron , Yu, Alexander , Jang, Michelle, Rubart, Michael , Zhu, Wuqiang , Liao, Jun , Adam, Henderson , Yang, Aaron , Yu, Alexander , Jang, Michelle , Rubart, Michael , Xie, Jingwei , Zhu, Wuqiang , Chen, Houjia , Xie, Jingwei

Mayo Clinic

Circulation Research | August 15, 2024 | Volume: 135 | Issue: 7 | Pages: 777-798

10.1161/circresaha.124.324608 | PMID 39145385 Get It

BACKGROUND: Apelin is an endogenous prepropeptide that regulates cardiac homeostasis and various physiological processes. Intravenous injection has been shown to improve cardiac contractility in patients with heart failure. However, its short half-life prevents studying its impact on left ventricular remodeling in the long term. Here, we aim to study whether microparticle-mediated slow release of apelin improves heart function and left ventricular remodeling in mice with myocardial infarction (MI). METHODS: A cardiac patch was fabricated by embedding apelin-containing microparticles in a fibrin gel scaffold. MI was induced via permanent ligation of the left anterior descending coronary artery in adult C57BL/6J mice followed by epicardial patch placement immediately after (acute MI) or 28 days (chronic MI) post-MI. Four groups were included in this study, namely sham, MI, MI plus empty microparticle-embedded patch treatment, and MI plus apelin-containing microparticle-embedded patch treatment. Cardiac function was assessed by transthoracic echocardiography. Cardiomyocyte morphology, apoptosis, and cardiac fibrosis were evaluated by histology. Cardioprotective pathways were determined by RNA sequencing, quantitative polymerase chain reaction, and Western blot. RESULTS: The level of endogenous apelin was largely reduced in the first 7 days after MI induction and it was normalized by day 28. Apelin-13 encapsulated in poly(lactic-co-glycolic acid) microparticles displayed a sustained release pattern for up to 28 days. Treatment with apelin-containing microparticle-embedded patch inhibited cardiac hypertrophy and reduced scar size in both acute and chronic MI models, which is associated with improved cardiac function. Data from cellular and molecular analyses showed that apelin inhibits the activation and proliferation of cardiac fibroblasts by preventing transforming growth factor-β–mediated activation of Smad2/3 (supporessor of mothers against decapentaplegic 2/3) and downstream profibrotic gene expression. CONCLUSIONS: Poly(lactic-co-glycolic acid) microparticles prolonged the apelin release time in the mouse hearts. Epicardial delivery of the apelin-containing microparticle-embedded patch protects mice from both acute and chronic MI-induced cardiac dysfunction, inhibits cardiac fibrosis, and improves left ventricular remodeling.
Surveillance Imaging vs Symptomatic Recurrence Detection and Survival in Stage II-III Breast Cancer (AFT-01)
Schumacher, Jessica R. , Neuman, Heather B. , Yu, Menggang , Vanness, David J. , Si, Yajuan , Burnside, Elizabeth S. , Ruddy, Kathryn J. , Schrag, Deborah , Edge, Stephen B. , Zhang, Ying , Jacobs, Elizabeth A. , Havlena, Jeffrey , Francescatti, Amanda B. , Winchester, David P., McKellar, Daniel P., Spears, Patricia A. , Kozower, Benjamin D. , Chang, George J. , Greenberg, Caprice C. , Group, for the Alliance ACS-CRP CCDR Breast Cancer Surveillance Working, Green, Bettye, Perlmutter, Jane , Berger, Elizabeth R. , Punglia, Rinaa S. , Chen, Ronald, Brys, Nicole, Schrag, Deborah , Burnside, Elizabeth S , Yu, Menggang , Partridge, Ann H. , Group, for the Alliance ACS-CRP CCDR Breast Cancer Surveillance Working, Ballman, Karla V. , Gavin, Patrick G. , Chen, Ronald C. , Adesoye, Taiwo

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 1, 2022 | Volume: 114 | Issue: 10 | Pages: 1371-1379

10.1093/jnci/djac131 | PMID 35913454 Get It

Abstract Background Guidelines for follow-up after locoregional breast cancer treatment recommend imaging for distant metastases only in the presence of patient signs and/or symptoms. However, guidelines have not been updated to reflect advances in imaging, systemic therapy, or the understanding of biological subtype. We assessed the association between mode of distant recurrence detection and survival. Methods In this observational study, a stage-stratified random sample of women with stage II-III breast cancer in 2006-2007 and followed through 2016 was selected, including up to 10 women from each of 1217 Commission on Cancer facilities (n = 10 076). The explanatory variable was mode of recurrence detection (asymptomatic imaging vs signs and/or symptoms). The outcome was time from initial cancer diagnosis to death. Registrars abstracted scan type, intent (cancer-related vs not, asymptomatic surveillance vs not), and recurrence. Data were merged with each patient’s National Cancer Database record. Results Surveillance imaging detected 23.3% (284 of 1220) of distant recurrences (76.7%, 936 of 1220 by signs and/or symptoms). Based on propensity-weighted multivariable Cox proportional hazards models, patients with asymptomatic imaging compared with sign and/or symptom detected recurrences had a lower risk of death if estrogen receptor (ER) and progesterone receptor (PR) negative, HER2 negative (triple negative; hazard ratio [HR] = 0.73, 95% confidence interval [CI] = 0.54 to 0.99), or HER2 positive (HR = 0.51, 95% CI = 0.33 to 0.80). No association was observed for ER- or PR-positive, HER2-negative (HR = 1.14, 95% CI = 0.91 to 1.44) cancers. Conclusions Recurrence detection by asymptomatic imaging compared with signs and/or symptoms was associated with lower risk of death for triple-negative and HER2-positive, but not ER- or PR-positive, HER2-negative cancers. A randomized trial is warranted to evaluate imaging surveillance for metastases results in these subgroups.
Influence of radiation therapy on the outcome of T1-2N0M0 triple-negative breast cancer: A SEER population-based retrospective analysis.
Li, Huan , Chen, Yajuan , Shu, Yongqian , Guan, Xiaoxiang , Wang, Xin , Tang, Lin , Wang, Yucai

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: e12073-e12073

10.1200/jco.2019.37.15_suppl.e12073 Get It

e12073 Background: For T1-2N0M0 breast cancer after surgery and axillary staging, the current NCCN guideline recommends radiation therapy (RT) after lumpectomy but not total mastectomy unless there is a positive or less than 1 mm negative margin. This recommendation is regardless of hormonal status. Triple-negative breast cancer is a generally considered more aggressive compared with hormone positive breast cancer. We sought to investigate whether there is a survival benefit of RT in T1-2N0M0 TNBC. Methods: A Population-based retrospective analysis was performed using the Surveillance, Epidemiology, and End Results (SEER) database. Patients included in the analysis were divided into three groups according to surgery modality and RT: breast conservation therapy (BCT, i.e., lumpectomy + RT), mastectomy alone, and mastectomy + RT. The survival endpoints were breast cancer-specific survival (BCSS) and overall survival (OS), and survival analysis was performed using the Kaplan-Meier method. Results: A total of 22473 female with T1-2N0M0 TNBC diagnosed between 2010 and 2015 were included, with 13395 (60%) T1 and 9078 (40%) T2 cases. Surgery, RT and chemotherapy was done in 21674 (96%), 9633 (43%) and 14651 (65%) patients, respectively. Patients who underwent RT were older ( > 50 years, 78% vs 72%, P< 0.001), had fewer T2 (35% vs 44%, P< 0.001) tumor, and had more chemotherapy utilization (72% vs 60%, P< 0.001). 8807 patients had BCT; 8329 had mastectomy alone and 635 had mastectomy + RT. The 5-year BCSS rate was 94.3% for BCT, 93.3% for mastectomy alone ( P= 0.009 vs BCT), and 83.7% for mastectomy + RT ( P< 0.001 vs BCT and P< 0.001 vs mastectomy alone), respectively. The 5-year OS rate was 88.6% for BCT, 83.0 % for mastectomy alone ( P< 0.001 vs BCT), and 79.6% for mastectomy + RT ( P< 0.001 vs BCT and P= 0.190 vs mastectomy alone), respectively. Conclusions: In patients with T1-2N0M0 TNBC, BCT was associated with superior BCSS and OS compared to mastectomy with or without RT. After mastectomy, there was no evidence of survival benefit of RT, with worse BCSS and similar OS.
Asymptomatic distant recurrence detection and survival in early stage breast cancer: A nationally representative study.
Neuman, Heather B. , Zhang, Ying , Si, Yajuan , Ruddy, Kathryn J. , Edge, Stephen B. , Jacobs, Elizabeth A. , Havlena, Jeffrey , Francescatti, Amanda B. , Spears, Patricia A. , Winchester, David P., McKellar, Daniel P., Chang, George J. , Kozower, Benjamin D. , Greenberg, Caprice C. , Schumacher, Jessica R. , Yu, Menggang , Vanness, David J. , Burnside, Elizabeth S. , Partridge, Ann H. , Schrag, Deborah

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 35 | Issue: 15_suppl | Pages: 6520-6520

10.1200/jco.2017.35.15_suppl.6520 Get It

6520 Background: Breast cancer follow-up guidelines recommend imaging for distant metastases only in the presence of signs/symptoms. However, data supporting this recommendation predates the current era of improved imaging and targeted therapies based on molecular subtype. The objective was to assess the relationship between mode of distant recurrence detection and survival. Methods: A stage-stratified random sample of Stage II-III breast cancer patients diagnosed in 2006-7 was selected from NCDB records from 1,217 CoC-accredited facilities (10/hospital n = 10,853). Women were categorized by subtype: 1) ER or PR+/HER2-; 2) ER and PR-/Her2- (triple negative); 3) HER2+. Medical records abstracted for 5-years post-surgery supplemented NCDB data and assessed distant recurrence and mode of detection (prompted by signs/symptoms or surveillance imaging), imaging (chest CT, abdomen/pelvis CT/MRI, head CT/MRI, bone scan, PET/CT), death date. The relationship between mode of recurrence detection and days from initial cancer diagnosis to death was assessed using propensity-weighted multivariable Cox proportional hazards regression stratified by subtype. Propensity weights, based on receipt of surveillance systemic imaging, accounted for sociodemographic and tumor/treatment factors. Results: 5-year distant recurrence was 22.3% for triple negative, 14.8% HER2+, and 11.2% for ER or PR+/ HER2- patients. Asymptomatic imaging detected recurrence in 22.9% and signs/symptoms in 77.1%. Patients with asymptomatic as compared to sign/symptom detected recurrences had reduced risk of death in 5 years if triple negative (HR = 0.68, 95% CI = 0.50-0.93) or HER2+ (HR = 0.40, 95% CI = 0.24-0.65) with no significant association for ER or PR+/HER2- (HR = 1.2, 95% CI = 0.88-1.51). This translated to a between-group difference in weighted median survival of 5 months for triple negative and 13 months for HER2+ patients. Conclusions: This is the first nationally representative study to show a survival advantage with asymptomatic detection of distant metastases for patients, with the benefit limited to triple negative and HER2+ disease. Further research to confirm observational findings is warranted.
A functional variant in HOXA11-AS , a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer
Richards, Edward J., Permuth‐Wey, Jennifer, Li, Yajuan , Coppola, Domenico , Reid, Brett M. , Lin, Hui‐Yi , Teer, Jamie K. , Birrer, Michael J. , Lawrenson, Kate , Monteiro, Álvaro N.A. , Schildkraut, Joellen M. , Goode, Ellen L. , Gayther, Simon A. , Sellers, Thomas A. , Cheng, Jin Q. , Chen, Y. Ann , Berchuck, Andrew , Lawrenson, Kate , Monteiro, Alvaro N , Lin, Hui-Yi

Mayo Clinic

Oncotarget | September 29, 2015 | Volume: 6 | Issue: 33 | Pages: 34745-34757

10.18632/oncotarget.5784 | PMID 26430965 Get It